LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel: Comparative dose effectiveness of intravenous and intrathecal AAV9.CB7.hIDS, RGX-121, in mucopolysaccharidosis type II mice.

    Smith, Miles C / Belur, Lalitha R / Karlen, Andrea D / Erlanson, Olivia / Furcich, Justin / Lund, Troy C / Seelig, Davis / Kitto, Kelley F / Fairbanks, Carolyn A / Kim, Kwi Hye / Buss, Nick / McIvor, R Scott

    Molecular therapy. Methods & clinical development

    2024  Band 32, Heft 1, Seite(n) 101201

    Abstract: Mucopolysaccharidosis type II (MPS II) is an X-linked recessive lysosomal disease caused by iduronate-2-sulfatase (IDS) deficiency, leading to accumulation of glycosaminoglycans (GAGs) and the emergence of progressive disease. Enzyme replacement therapy ... ...

    Abstract Mucopolysaccharidosis type II (MPS II) is an X-linked recessive lysosomal disease caused by iduronate-2-sulfatase (IDS) deficiency, leading to accumulation of glycosaminoglycans (GAGs) and the emergence of progressive disease. Enzyme replacement therapy is the only currently approved treatment, but it leaves neurological disease unaddressed. Cerebrospinal fluid (CSF)-directed administration of AAV9.CB7.hIDS (RGX-121) is an alternative treatment strategy, but it is unknown if this approach will affect both neurologic and systemic manifestations. We compared the effectiveness of intrathecal (i.t.) and intravenous (i.v.) routes of administration (ROAs) at a range of vector doses in a mouse model of MPS II. While lower doses were completely ineffective, a total dose of 1 × 10
    Sprache Englisch
    Erscheinungsdatum 2024-01-30
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2872938-9
    ISSN 2329-0501 ; 2329-0501
    ISSN (online) 2329-0501
    ISSN 2329-0501
    DOI 10.1016/j.omtm.2024.101201
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Generation and characterization of an immunodeficient mouse model of mucopolysaccharidosis type II.

    Smith, Miles C / Belur, Lalitha R / Karlen, Andrea D / Podetz-Pedersen, Kelly / Erlanson, Olivia / Laoharawee, Kanut / Furcich, Justin / Lund, Troy C / You, Yun / Seelig, Davis / Webber, Beau R / McIvor, R Scott

    Molecular genetics and metabolism

    2023  Band 138, Heft 4, Seite(n) 107539

    Abstract: Mucopolysaccharidosis type II (Hunter syndrome, MPS II) is an inherited X-linked recessive disease caused by deficiency of iduronate-2-sulfatase (IDS), resulting in the accumulation of the glycosaminoglycans (GAG) heparan and dermatan sulfates. Mouse ... ...

    Abstract Mucopolysaccharidosis type II (Hunter syndrome, MPS II) is an inherited X-linked recessive disease caused by deficiency of iduronate-2-sulfatase (IDS), resulting in the accumulation of the glycosaminoglycans (GAG) heparan and dermatan sulfates. Mouse models of MPS II have been used in several reports to study disease pathology and to conduct preclinical studies for current and next generation therapies. Here, we report the generation and characterization of an immunodeficient mouse model of MPS II, where CRISPR/Cas9 was employed to knock out a portion of the murine IDS gene on the NOD/SCID/Il2rγ (NSG) immunodeficient background. IDS
    Mesh-Begriff(e) Humans ; Animals ; Mice ; Mucopolysaccharidosis II/therapy ; Mice, Inbred NOD ; Mice, SCID ; Iduronate Sulfatase/genetics ; Glycosaminoglycans
    Chemische Substanzen Iduronate Sulfatase (EC 3.1.6.13) ; Glycosaminoglycans
    Sprache Englisch
    Erscheinungsdatum 2023-02-10
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 1418518-0
    ISSN 1096-7206 ; 1096-7192
    ISSN (online) 1096-7206
    ISSN 1096-7192
    DOI 10.1016/j.ymgme.2023.107539
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Phenotypic Correction of Murine Mucopolysaccharidosis Type II by Engraftment of

    Smith, Miles C / Belur, Lalitha R / Karlen, Andrea D / Erlanson, Olivia / Podetz-Pedersen, Kelly M / McKenzie, Jessica / Detellis, Jenn / Gagnidze, Khatuna / Parsons, Geoffrey / Robinson, Nicholas / Labarre, Shelby / Shah, Saumil / Furcich, Justin / Lund, Troy C / Tsai, Hsing-Chen / McIvor, R Scott / Bonner, Melissa

    Human gene therapy

    2022  Band 33, Heft 23-24, Seite(n) 1279–1292

    Abstract: Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked recessive lysosomal disease caused by deficiency of iduronate-2-sulfatase (IDS). The absence of IDS results in the accumulation of the glycosaminoglycans (GAGs) heparan sulfate and ... ...

    Abstract Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked recessive lysosomal disease caused by deficiency of iduronate-2-sulfatase (IDS). The absence of IDS results in the accumulation of the glycosaminoglycans (GAGs) heparan sulfate and dermatan sulfate. Currently, the only approved treatment option for MPS II is enzyme replacement therapy (ERT), Elaprase. However, ERT is demanding for the patient and does not ameliorate neurological manifestations of the disease. Using an IDS-deficient mouse model that phenocopies the human disease, we evaluated hematopoietic stem and progenitor cells (HSPCs) transduced with a lentiviral vector (LVV) carrying a codon-optimized human IDS coding sequence regulated by a ubiquitous MNDU3 promoter (MNDU3-IDS). Mice treated with MNDU3-IDS LVV-transduced cells showed supraphysiological levels of IDS enzyme activity in plasma, peripheral blood mononuclear cells, and in most analyzed tissues. These enzyme levels were sufficient to normalize GAG storage in analyzed tissues. Importantly, IDS levels in the brains of MNDU3-IDS-engrafted animals were restored to 10-20% than that of wild-type mice, sufficient to normalize GAG content and prevent emergence of cognitive deficit as evaluated by neurobehavioral testing. These results demonstrate the potential effectiveness of
    Sprache Englisch
    Erscheinungsdatum 2022-11-23
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1028152-6
    ISSN 1557-7422 ; 1043-0342
    ISSN (online) 1557-7422
    ISSN 1043-0342
    DOI 10.1089/hum.2022.141
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang